Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
INFU 
InfuSystems Holdings Inc (INFU)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: INFU (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.
1 Year Target Price $14.12
1 Year Target Price $14.12
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.71% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 128.37M USD | Price to earnings Ratio 40.8 | 1Y Target Price 14 |
Price to earnings Ratio 40.8 | 1Y Target Price 14 | ||
Volume (30-day avg) - | Beta 1.81 | 52 Weeks Range 4.61 - 9.97 | Updated Date 06/29/2025 |
52 Weeks Range 4.61 - 9.97 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.15 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 2.32% | Operating Margin (TTM) -1.1% |
Management Effectiveness
Return on Assets (TTM) 5.11% | Return on Equity (TTM) 5.94% |
Valuation
Trailing PE 40.8 | Forward PE - | Enterprise Value 160027615 | Price to Sales(TTM) 0.93 |
Enterprise Value 160027615 | Price to Sales(TTM) 0.93 | ||
Enterprise Value to Revenue 1.16 | Enterprise Value to EBITDA 7.55 | Shares Outstanding 20975300 | Shares Floating 18279733 |
Shares Outstanding 20975300 | Shares Floating 18279733 | ||
Percent Insiders 6.48 | Percent Institutions 78.53 |
Analyst Ratings
Rating 5 | Target Price 14.12 | Buy - | Strong Buy 4 |
Buy - | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
InfuSystems Holdings Inc
Company Overview
History and Background
InfuSystems Holdings Inc. was founded in 1987. It provides infusion therapy services, equipment, and related products to patients in the comfort of their homes or at ambulatory infusion suites. It has grown through acquisitions and organic expansion.
Core Business Areas
- Integrated Therapy Services (ITS): Provides infusion pumps, supplies, and related clinical support services to oncology practices, hospitals, and other healthcare providers. Focuses on oncology, pain management, and other specialty therapies.
- Durable Medical Equipment (DME): Offers rental and sale of durable medical equipment, primarily focusing on negative pressure wound therapy (NPWT) pumps and related supplies.
Leadership and Structure
Richard DiIorio is the Chief Executive Officer. The company operates with a functional organizational structure with key departments overseeing operations, finance, sales, and marketing.
Top Products and Market Share
Key Offerings
- Infusion Pumps and Supplies: Provides a range of infusion pumps, supplies, and associated services for various therapies, particularly in oncology. Market share data is not readily available. Competitors include Baxter International (BAX) and ICU Medical (ICUI).
- Negative Pressure Wound Therapy (NPWT) Pumps: Offers NPWT pumps and related supplies for wound care. Market share data is not readily available. Competitors include Smith & Nephew (SNN) and 3M (MMM).
Market Dynamics
Industry Overview
The infusion therapy and DME market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. The market is competitive with several large and small players.
Positioning
InfuSystems Holdings Inc. occupies a niche position in the market, focusing on providing integrated therapy services and DME. Its competitive advantages include its established relationships with healthcare providers and its expertise in infusion therapy.
Total Addressable Market (TAM)
The global infusion therapy market is estimated to be worth billions of dollars. InfuSystems is positioned to capture a segment of this market through its specialized services and equipment.
Upturn SWOT Analysis
Strengths
- Established relationships with healthcare providers
- Expertise in infusion therapy
- Integrated therapy services
- Recurring revenue stream from rentals
Weaknesses
- High debt levels
- Dependence on key contracts
- Limited geographic diversification
- Smaller scale compared to larger competitors
Opportunities
- Expanding into new geographic markets
- Developing new therapies and applications for infusion therapy
- Acquiring smaller competitors
- Leveraging technology to improve efficiency and patient outcomes
Threats
- Increased competition
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- BAX
- ICUI
- SNN
- MMM
Competitive Landscape
InfuSystems faces competition from larger, more diversified companies. Its strengths include its specialized focus and established relationships, while its weaknesses include its smaller scale and higher debt levels.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions and organic expansion in the infusion therapy and DME markets.
Future Projections: Future growth projections depend on factors such as market demand, competitive landscape, and the company's ability to execute its growth strategy. Analyst estimates vary.
Recent Initiatives: Recent strategic initiatives may include acquisitions, partnerships, and new product launches.
Summary
InfuSystems is a specialized provider in infusion therapy and DME, focusing on integrated services. While it has established market presence and revenue, its high debt and dependence on contracts are concerns. Growth opportunities exist through expansion and new therapies. It needs to manage competition and reimbursement changes effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may not be precise. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InfuSystems Holdings Inc
Exchange NYSE MKT | Headquaters Rochester Hills, MI, United States | ||
IPO Launch date 2007-12-27 | President, CEO & Director Ms. Carrie A. Lachance B.S.N., M.B.A., R.N. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 502 | Website https://www.infusystem.com |
Full time employees 502 | Website https://www.infusystem.com | ||
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps and related products and services in the United States and Canada. It operates in two segments, Patient Services and Device Solutions. The company supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. It also sells and rents new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, the company offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.